News & Events
News & Events
November 8, 2018
Profiles in Business with Tucson Metro Chamber
C-Path President and CEO Martha Brumfield, Ph.D., talks about today’s drug discovery process, C-Path’s global impact and what’s next for the organization on the Tucson Metro Chamber’s Profiles in Business podcast.
November 5, 2018
Critical Path Institute Rebrands One of Its First Consortia to Highlight Focus on Alzheimer’s DiseaseCritical Path for Alzheimer’s Disease (CPAD) consortium’s refined, refocused mission centers on accelerating therapy development for AD and related forms of dementia TUCSON, Ariz., November 5, 2018 — The Critical Path Institute (C-Path) is pleased to announce that its Critical Path for Alzheimer’s Disease (CPAD) consortium has refined and refocused its mission in celebration of...
- November 1, 2018
November 1, 2018
C-Path, CHDI and CDISC Announce Therapeutic Area User Guide for Huntington’s DiseaseTUCSON, Ariz., NEW YORK and AUSTIN, Texas, November 1, 2018 — The Huntington’s Disease Regulatory Science Consortium (HD-RSC), launched in March 2018 by the Critical Path Institute (C-Path) and CHDI Foundation, today, along with the Clinical Data Interchange Standards Consortium (CDISC), announce the open availability of a newly developed Huntington’s Disease Therapeutic Area User Guide...
October 25, 2018
FNIH Biomarkers Consortium and Critical Path Institute Achieve the First Ever Qualification of a Clinical Safety Biomarker by the U.S. Food and Drug AdministrationMajor Milestone will Improve Detection of Drug-Induced Acute Kidney Injury in Clinical Trials. October 25, 2018 — The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium (BC) and the Critical Path Institute (C-Path) Predictive Safety Testing Consortium (PSTC) have received the first ever qualification of a clinical safety biomarker awarded by...